



Curis, Inc.  
Investor Relations Department  
4 Maguire Road  
Lexington, MA 02421  
United States

[Visit IR website](#)   
[Sign-up for email alerts](#)

#### NASDAQ: CRIS

Last Trade:	1.57
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.47 - 3.72
Volume	1

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Sep 22, 2017*  
[Curis to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 14, 2017*  
[Curis Announces Pricing of Public Offering of Common Stock](#)
- Sep 13, 2017*  
[Curis Announces Proposed Public Offering of Common Stock](#)
- Sep 11, 2017*  
[Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017](#)
- Sep 6, 2017*  
[Curis to Present at the Baird 2017 Global Healthcare Conference](#)

### Upcoming Events [\[ View all \]](#)

- Sep 25, 2017 3:35 PM ET*  
[2017 Cantor Fitzgerald Global Healthcare Conference](#)

### Events [\[ View all \]](#)

### Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 9, 2017*  
[Annual Report \(10-K\)](#)
- Apr 4, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)